Idorsia Ltd today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information
Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 . As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter. André C. Muller, Chief Financial Officer, commented:
"We have had many interactions with our bondholders in the past week. We are finalizing our proposed amendment to the terms and conditions of the bond, taking into account the bondholder needs as well as our objective to avoid unnecessary dilution. We expect to publish the invitation to the bondholders meeting in the next few days."Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients.
Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options.
Idorsia was listed on the SIX Swiss Exchange in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.Senior Vice President, Head of Investor Relations & Corporate Communicationsinvestor.relations@idorsia.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Idorsia Pharmaceuticals Ltd: Idorsia thanks Guy Braunstein for his years of service as he retiresGuy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland - March 22, 2024Idorsia Ltd (SIX: IDIA) today
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »
Idorsia Pharmaceuticals Ltd: Idorsia and Viatris successfully close the transaction for the global research and development collaborationAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ:
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »
Idorsia Pharmaceuticals Ltd: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesAd hoc announcement pursuant to Art. 53 LR TRYVIO (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »
NASDAQ-Titel Vanda Pharmaceuticals mit Kurssprung: Neues Medikament gegen bipolare Störungen von US-Behörde FDA genehmigtMit der Marktzulassung des Medikaments Fanapt erhofft sich der Hersteller Vanda Pharmaceuticals kommerzielle Behandlungsmöglichkeiten.
Herkunft: FinanzenNet - 🏆 78. / 55 Weiterlesen »
HotStocks USA: + 100% bei Fusion PharmaceuticalsAnbei erhaltet ihr eine Übersicht über die Werte, die vorbörslich an der Nasdaq am meisten Aufmerksamkeit bei den Anlegern erregen.
Herkunft: - 🏆 87. / 53 Weiterlesen »
EQS-News: Newron Pharmaceuticals S.p.A.: Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekanntEQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Jahresbericht Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekannt 19.03.2024 / 07:00 CET/CEST Für den
Herkunft: FN_Nachrichten - 🏆 88. / 53 Weiterlesen »